Results
1 -
10 of
64
(Click
here to explore results)
- Designing Multi-Target Drugs, Chapter 16 Discovery of the Anti-Psychotic Drug, Ziprasidone. John A. Lowe, III
, 2012
, Pages 263-269
- Drug Discovery for Psychiatric Disorders, CHAPTER 3 Monoaminergic Approaches for Treatment of Schizophrenia. David P. Rotella
, 2012
, Pages 35-55
- Emerging Drugs and Targets for Parkinson's Disease, CHAPTER 5 Pharmacologic Management of Dopaminergic‐Induced Dyskinesias in Parkinson’s Disease. Mildred D. Gottwald, Michael J. Aminoff
, 2013
, Pages 110-125
- Drug Discovery for Psychiatric Disorders, CHAPTER 19 Multi-target Drug Discovery for Psychiatric Disorders. Zoran Rankovic, Richard Morphy
, 2012
, Pages 510-533
- Drug Design Strategies: Computational Techniques and Applications, Chapter 4 QM Based Modelling. Timothy Clark
, 2012
, Pages 87-106
- Phenotypic Drug Discovery, Chapter 10 Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia. E. Leahy, M. Varney, D. Brunner
, 2021
, Pages 175-197
- Drug Discovery for Schizophrenia, CHAPTER 10 Optogenetic and Chemogenetic Tools for Drug Discovery in Schizophrenia. Dennis Kätzel, Dimitri M. Kullmann
, 2015
, Pages 234-272
- Drug Discovery for Schizophrenia, CHAPTER 8 GSK3 Networks in Schizophrenia. Jivan Khlghatyan, Gohar Fakhfouri, Jean-Martin Beaulieu
, 2015
, Pages 173-201
- Drug Discovery for Schizophrenia, CHAPTER 2 The Impact of Epigenetics in Schizophrenia Research. Peter J. Gebicke-Haerter
, 2015
, Pages 28-45
- Drug Discovery for Psychiatric Disorders, CHAPTER 2 The Pathophysiology of Schizophrenia. Armin Szegedi, Michael Egan
, 2012
, Pages 13-34